09606.HK
Duality Biotherapeutics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 180.70
−1.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 842.1M | 1.8B | 1.9B | 1.8B | 1.6M |
| Cost of Revenue | 1.1B | 1.2B | 1.2B | 427.7M | — |
| Gross Profit | (233.7M) | 561.8M | 784.7M | 1.4B | 1.6M |
| Operating Expenses | |||||
| R&D Expense | 1.1B | 809.5M | 836.7M | 559.0M | 339.9M |
| SG&A Expense | 170.6M | 168.6M | 39.8M | 36.7M | 15.1M |
| General & Admin Expense | 170.6M | — | 39.8M | 36.7M | 15.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 61.5M | — | 97.2M | (18.1M) | 15.2M |
| Total Operating Expenses | 1.3B | 978.1M | 973.7M | 577.5M | 370.2M |
| Cost and Expenses | 2.4B | 2.2B | 2.1B | 1.0B | 370.2M |
| Operating Income (EBIT) | (1.6B) | (416.3M) | (189.0M) | 781.4M | (368.6M) |
| Non-Operating | |||||
| Interest Income | — | 96.7M | 48.1M | 34.5M | 3.3M |
| Interest Expense | — | 1.2M | 250.0K | 188.0K | 75.0K |
| Net Interest Income | 56.7M | 95.6M | 47.9M | 34.3M | 3.2M |
| Other Non-Op Income/Expense | 122.3M | (2.1B) | (825.6M) | (983.6M) | (18.5M) |
| Non-Operating Income (excl Interest) | (17.6M) | 2.1B | 825.3M | 983.4M | 18.4M |
| EBT (Pre-Tax Income) | (1.4B) | (2.5B) | (1.0B) | (202.2M) | (387.1M) |
| Income Tax Expense | — | — | 35.9M | 155.3M | — |
| Bottom Line | |||||
| Net Income | (1.4B) | (2.5B) | (1.1B) | (357.5M) | (387.1M) |
| Earnings from Cont. Ops | (1.4B) | (2.5B) | (1.1B) | (357.5M) | (387.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.4B) | (2.5B) | (1.1B) | (357.5M) | (387.1M) |
| Per Share | |||||
| Basic EPS | (HK$16.08) | (HK$38.79) | (HK$12.63) | (HK$4.30) | (HK$4.65) |
| Diluted EPS | (HK$16.08) | (HK$38.79) | (HK$12.63) | (HK$4.30) | (HK$4.65) |
| Revenue Per Share | HK$9.36 | HK$27.68 | HK$23.34 | HK$21.48 | HK$0.02 |
| Shares | |||||
| Basic Shares Outstanding | 90.0M | 65.2M | 83.2M | 83.2M | 83.2M |
| Diluted Shares Outstanding | 90.0M | 65.2M | 83.2M | 83.2M | 83.2M |
| Profitability Metrics | |||||
| EBITDA | (1.5B) | (2.5B) | (1.0B) | (197.1M) | (385.2M) |
| D&A | 8.0M | 12.0M | 7.9M | 5.0M | 1.8M |
| EBIT | (1.5B) | (2.5B) | (1.0B) | (202.1M) | (387.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026